Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck

Slide schematic 5/5

callout 1/1 chart 1/1 list 1/1 source-note 1/1 title 1/1

Components 5

primary bar-horizontal bullet source-note headline

Tools 1

The slide presents a clear and concise key takeaway, grabbing the audience's attention (A), raising interest (I) by highlighting TL1A's potential, creating desire (D) for a best-in-class agent, and encouraging action (A) with a $10.8B acquisition.

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 1

comparison_frame 80%

Comparison of clinical efficacy across drug classes

Find anything

The chart compares clinical remission rates across different drug classes (TL1A, a4b7, IL-23s, TNFas, S1P1s, JAKs) with a safety gradient indicated on the Y-axis.